COMMUNIQUÉS West-GlobeNewswire

Tetra Bio-Pharma Convenes First National Medical Advisory Board
04/12/2018
Key Opinion Leaders Weigh in on Scientific Research in Cannabinoids ORLEANS, Ontario, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF), – announced that it [...]
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04/12/2018
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
04/12/2018
Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product [...]
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
04/12/2018
HAIFA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that [...]
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
04/12/2018
Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile [...]
RavenQuest Begins Cannabis Sales
04/12/2018
VANCOUVER, British Columbia, Dec. 04, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT ) is pleased to announce that it is concluding its first [...]
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
04/12/2018
PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of [...]
Transactions in relation to share buyback program
04/12/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
04/12/2018
Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the [...]
Rule 2.9 Announcement
04/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 4 December 2018 [...]
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04/12/2018
SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with [...]
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
04/12/2018
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching Among Patients with [...]
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
04/12/2018
P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a [...]
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
04/12/2018
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators [...]
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
04/12/2018
82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb) Safety Profile of UCART19 Appears Manageable with No Evidence of Moderate or Severe Graft [...]
Driven Inc. to Present at the 11th Annual LD Micro Main Event
04/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Driven Inc. (OTC: RBOS), a cannabis delivery service, announced today that they will be presenting at the 11th Annual LD Micro Main Event. The conference is being held on [...]
REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Italy
04/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” Or The “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of its recently [...]
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
04/12/2018
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md., Dec. 03, 2018 ( [...]
National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis
03/12/2018
Recommends Treat-to-Target Approach, First-Line Use of TNFi Biologics, and Smoking Cessation Atlanta, Dec. 03, 2018 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) [...]

Pages